Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Canvas Wealth Advisors LLC

Canvas Wealth Advisors LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 12.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,039 shares of the medical equipment provider’s stock after selling 430 shares during the period. Canvas Wealth Advisors LLC’s holdings in Hologic were worth $219,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic in the third quarter valued at $25,000. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at $26,000. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Cromwell Holdings LLC raised its stake in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of HOLX stock opened at $65.24 on Tuesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. Hologic, Inc. has a 1 year low of $63.62 and a 1 year high of $84.67. The stock’s 50-day moving average is $72.06 and its two-hundred day moving average is $77.67. The firm has a market cap of $14.73 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.88% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. UBS Group increased their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Evercore ISI dropped their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.